MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…

Biotechnology

CH, Zug [HQ]

Overview
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Outstanding & Floating

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. It's perfect to get a quick briefing regarding the shareholder structure of MoonLake Immunotherapeutics

Beneficial Owners Beta

Beneficial owners hold at least 10% of the stocks outstanding. Palmy retrieves this information from the most reliable, audited format which presents the data, the proxy statement.

Soon Available - Stay Tuned